キュレーション · ヘルスケア

Biotech

InspectStocks 編集Published 2026年10月14日19 companies0 followers

Drug developers with approved medicines, built mainly on biologic and genetic science.

AI モデルの助けを借りてグループ分けし、編集部が確認しました。各企業の下の一行が、ここに入っている理由を説明します。

Download image

カードティア

株価は2026年11月11日の終値です（IEX取引所のデータ）。

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29.0%

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap $138.7BP/E 35.22
$547.02+26.0%1Y
Since added +12.7%
B+
成長と現金
力強く成長
Business trend
安定
Business quality
高い
Getting better
改善中
Revenue
$13B+10.5%
Profit
$4B+8.2%
Free cash flow
$3.2B-4.0%
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap $101.3BP/E 21.18
$959.45+41.5%1Y
Since added +27.4%
C+
成長と現金
成長中
Business trend
加速
Business quality
高い
Getting better
改善中
Revenue
$16.9B+18.6%
Profit
$4.8B+5.2%
Free cash flow
$3.8B-9.4%
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap $210.5BPERなし（営業損失）
$169.73+40.9%1Y
Since added +14.8%
A
成長と現金
力強く成長
Business trend
安定
Business quality
まちまち
Getting better
改善中
Revenue
$31B+6.5%
Profit
-$3.9B-147.6%
Free cash flow
$13.8B+50.4%
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap $21.4BP/E 68.58
$159.80-64.7%1Y
Since added -28.6%
B+
成長と現金
力強く成長
Business trend
減速
Business quality
高い
Getting better
改善中
Revenue
$3.7B+65.2%
Profit
$2.6B+2,136.9%
Free cash flow
$465.4M+1,192.7%
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap $37.5BP/E 109.22
$253.39+56.9%1Y
Since added +10.7%
A
成長と現金
力強く成長
Business trend
安定
Business quality
堅実
Getting better
まちまち
Revenue
$10.3B+2.3%
Profit
$347.5M-78.4%
Free cash flow
$2.1B-10.1%
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap $26.5BPERなし（営業損失）
$120.64-37.9%1Y
Since added +24.7%
C-
成長と現金
成長中
Business trend
安定
Business quality
弱い
Getting better
まちまち
Revenue
$1.5B+240.0%
Profit
-$605.6M+48.8%
Free cash flow
-$627.6M+30.7%
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap $25.4BP/E 22.48
$595.58+29.0%1Y
Since added +9.6%
C+
成長と現金
力強く成長
Business trend
減速
Business quality
高い
Getting better
大きく改善
Revenue
$3.2B+1.9%
Profit
$1.2B-3.2%
Free cash flow
$867.2M-22.7%
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap $17.6BP/E 25.87
$174.35+18.7%1Y
Since added +29.0%
A+
成長と現金
力強く成長
Business trend
加速
Business quality
高い
Getting better
改善中
Revenue
$3.7B+38.0%
Profit
$702.5M+64.1%
Free cash flow
$1B+75.3%
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap $100.6BPERなし（営業損失）
$248.70+831.1%1Y
Since added +15.0%
C-
成長と現金
成長中
Business trend
加速
Business quality
弱い
Getting better
悪化中
Revenue
$2.5B+13.1%
Profit
-$2.8B+10.5%
Free cash flow
-$2B+25.7%
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap $11.3BNo P/E
$58.32+5.4%1Y
Since added +7.3%
B
成長と現金
力強く成長
Business trend
安定
Business quality
まちまち
Getting better
改善中
Revenue
$3.7B+18.1%
Profit
-$19.1M-103.7%
Free cash flow
$557.9M-33.0%
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap $24.9BP/E 65.01
$122.23+12.9%1Y
Since added +12.6%
C
利益と純資産
成長中
Business quality
まちまち
Getting better
大きく改善
Revenue
$6B+24.9%
Profit
$403.4M-66.1%
Free cash flow
$892.1MNo comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap $17.3BP/E 21.17
$70.71+62.2%1Y
Since added +18.8%
A+
成長と現金
力強く成長
Business trend
安定
Business quality
高い
Getting better
改善中
Revenue
$2.5B+9.1%
Profit
$885.1M+30.6%
Free cash flow
$1.2B+48.9%
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap $22BPERなし（営業損失）
$87.64-21.5%1Y
Since added -1.5%
F
成長と現金
まちまち
Business trend
縮小
Business quality
まちまち
Getting better
改善中
Revenue
$2.7B-23.2%
Profit
-$1.6B-157.7%
Free cash flow
$314M+456.5%
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap $15.9BP/E 80.84
$248.18+81.5%1Y
Since added +18.0%
A
成長と現金
力強く成長
Business trend
安定
Business quality
まちまち
Getting better
改善中
Revenue
$4.7B+13.5%
Profit
$206M+155.9%
Free cash flow
$1.6B+21.3%
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap $11.6BP/E 25.36
$101.69+44.0%1Y
Since added -7.2%
A+
成長と現金
力強く成長
Business trend
安定
Business quality
高い
Getting better
改善中
Revenue
$1.8B+45.0%
Profit
$485.4M-18.5%
Free cash flow
$885.9M+47.1%
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap $16.1BPERなし（営業損失）
$259.10+30.1%1Y
Since added +16.0%
D
利益と純資産
まちまち
Business quality
まちまち
Getting better
改善中
Revenue
$1.2B+113.4%
Profit
-$254.8M+39.7%
Free cash flow
-$293.2M+54.2%
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap $15.5BPERなし（営業損失）
$79.53+20.1%1Y
Since added +25.6%
B
成長と現金
力強く成長
Business trend
安定
Business quality
まちまち
Getting better
悪化中
Revenue
$945.5M+167.3%
Profit
-$573.8M+28.6%
Free cash flow
-$369.8M+36.9%
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap $8.2BP/E 58.68
$74.52-4.9%1Y
Since added -36.7%
A+
成長と現金
力強く成長
Business trend
加速
Business quality
高い
Getting better
まちまち
Revenue
$963.6M+30.0%
Profit
$162.3M+52.9%
Free cash flow
$194.6M+19.2%
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap $9.2BP/E 41.90
$308.82+52.1%1Y
Since added -3.9%
A+
成長と現金
力強く成長
Business trend
安定
Business quality
高い
Getting better
改善中
Revenue
$470M+26.0%
Profit
$225.2M+13.2%
Free cash flow
$310.1M+87.3%
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.